Nitric oxide/redox-based signalling as a therapeutic target for penile disorders

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 3, 2006, Pages 445-457

  Burnett, Arthur L ^a   Musicki, Biljana ^a   Jin, Liming ^a   Bivalacqua, Trinity J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Erectile dysfunction; Guanylate cyclase activator; Nitric oxide synthase (NOS); Nitrosative stress; Oxidative stress; Penile fibrosis; Phosphodiesterase type 5 inhibitor (PDE 5); Priapism; Reactive nitrogen species (RNS); Reactive oxygen species (ROS); Signal transduction

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE ACTIVATOR; LINSIDOMINE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; PAPAVERINE; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PYRIDAZINE DERIVATIVE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; S NITROSOTHIOL; SILDENAFIL; SILDENAFIL NITRATE; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ANTIOXIDANT ACTIVITY; CHEMICAL INTERACTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; FLUSHING; HOMEOSTASIS; HUMAN; INJECTION SITE PAIN; MALE; MYALGIA; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PENILE BLOOD VESSEL; PENILE FIBROSIS; PENIS DISEASE; PENIS ERECTION; PEYRONIE DISEASE; PREDICTION; PRIAPISM; RAT; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMPOTENCE; MALE; NITRIC OXIDE; OXIDATION-REDUCTION; PENILE DISEASES; SIGNAL TRANSDUCTION;

EID: 33745479208     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.3.445     Document Type: Review

References (128)

1. KEITH M, GERANMAYEGAN A, SOLE MJ et al.: Increased oxidative stress in patients with congestive heart failure. J. Am. Coll. Cardiol (1998) 31:1352-1356.
2. SANTINI SA, SPADA C, BONONI F et al.: Liver, pancreas and biliary tract enhanced lipoperoxidation products in pure pancreatic juice: evidence for organ-specific oxidative stress in chronic pancreatitis. Dig. Liver Dis. (2003) 35:888-892.
3. MODLINGER PS, WILCOX CS, ASLAM S: Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin. Nephrol. (2004) 24:354-365.
4. CHONG ZZ, LI F, MAIESE K: Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res. Brain Res. Rev. (2005) 49:1-21.
5. STAMLER JS, SINGEL DJ, LOSCALZO J: Biochemistry of nitric oxide and its redox-activated forms. Science (1992) 258:1898-1902.
6. FORMAN HJ, FUKUTO JM, TORRES M: Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am. J. Physiol. Cell. Physiol. (2004) 287:C246-C256.
7. AZADZOI KM, GOLDSTEIN I, SIROKY MB, TRAISH AM, KRANE RJ, SAENZ DE TEJADA I: Mechanisms of ischemia-induced cavernosal smooth muscle relaxation impairment in a rabbit model of vasculogenic erectile dysfunction. J. UroL (1998) 160:2216-2222.
8. BYRNE RR, HENRY GD, RAO DS et al.: Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J. Urol. (2001) 165:1310-1315.
9. CHAMPION HC, BIVALACQUA TJ, TAKIMOTO F, KASS DA, BURNETT AL: Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc. Natl. Acad. Sci. USA (2005) 102:1661-1666.
10. GONZALEZ-CADAVID NF, RAJFER J: Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp. Gerontol. (2004) 39:1705-1712.
11. MULHALL JP, GRAYDON RJ: The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int. J. Impot. Res. (1996) 8:91-94.
12. SIKKA SC, HELLSTROM WJ: Role of oxidative stress and antioxidants in Peyronie's disease. Int. J. Impot. Res. (2002) 14:353-360.
13. ADAIKAN PG, NG SC: Physiological significance of nitrergic transmission in human penile erection. Asian J. Androl. (2000) 2:51-56.
14. BURNETT AL: Nitric oxide regulation of penile erection: biology and therapeutic implications. J. Androl. (2002) 23:S20-S26.
15. GONZALEZ-CADAVID NF, RAJFER J: Therapeutic stimulation of penile nitric oxide synthase (NOS) and related pathways. Drugs Today (2000) 36:163-174.
16. CARSON CC, LUE TF: Phosphodiesterase Type 5 inhibitors for erectile dysfunction. BJU Int. (2005) 96:257-280.
17. SALVEMINI D, MARINO MH: Inducible nitric oxide synthase and inflammation. Expert Opin. Investig. Drugs (1998) 7:65-75.
18. MONCADA S, HIGGS EA: The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol, (2006) 147(Suppl. 1):S193-S201.
19. BOEHNING D, SNYDER SH: Novel neural modulators. Ann. Rev. Neurosci. (2003) 26:105-131.
20. NATHAN C: Nitric oxide as a secretory product of mammalian cells. FASEB J. (1992) 6:3051-3064.
21. KNOWLES RG, MONCADA S: Nitric oxide synthases in mammals. Biochem. J. (1994) 298:249-258.
22. CRAWFORD JH, WHITE CR, PATEL RP: Vasoactivity of S-nitrosohemoglobin: role of oxygen, heme, and NO oxidation states. Blood (2003) 101:4408-4415.
23. WANG X, TANUS-SANTOS JE, REITER CD et al.: Biological activity of nitric oxide in the plasmatic compartment. Proc. Natl. Acad. Sci. USA (2004) 101:11477-11482.
24. STAMLER JS, MEISSNER G: Physiology of nitric oxide in skeletal muscle. Physiol. Rev. (2001) 81:209-237.
25. SESSA WC: Regulation of endothelial derived nitric oxide in health and disease. Mem. Inst. Oswaldo Cruz. (2005) 100(Suppl. 1):15-18.
26. PERRY JM, MARLETTA MA: Effects of transition metals on nitric oxide synthase catalysis. Proc. Natl. Acad. Sci. USA (1998) 95:11101-11106.
27. COOPER CE: Nitric oxide and iron proteins. Biochim. Biophys. Acta (1999) 1411:290-309.
28. FRANCIS SH, TURKO IV, CORBIN JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid. Res. Mol. Biol. (2001) 65:1-52.
29. RYBALKIN SD, YAN C, BORNFELDT KE, BEAVO JA: Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. (2003) 93:290-291.
30. SENZAKI H, SMITH CJ, JUANG GJ et al: Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. (2001) 15:1718-1726.
31. BENDER AT, BEAVO JA: Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Neurochem. Int. (2004) 45:853-857.
32. LI JM, SHAH AM: Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 287:R1014-R1030.
33. KIMURA H, SAWADA T, OSHIMA S, KOZAWA K, ISHIOKA T, KATO M: Toxicity and roles of reactive oxygen species. Curr. Drug Targets Inflamm. Allergy (2005) 4:489-495.
34. BERRY CE, HARE JM: Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. (2004) 555:589-606.
35. GRIENDLING KK, SORESCU D, USHIO-FUKAI M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. (2000) 86:494-501.
36. KUZKAYA N, WEISSMANN N, HARRISON DG, DIKALOV S: Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem. (2003) 278:22546-22554.
37. LEE HC, WEI YH: Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int. J. Biochem. Cell Biol. (2005) 37:822-834.
38. BALAGOPALAKRISHNA C, MANOHARAN PT, ABUGO OO, RIFKIND JM: Production of superoxide from hemoglobin-bound oxygen under hypoxic conditions. Biochemistry (1996) 35:6393-6398.
39. ALVAREZ B, RADI R: Peroxynitrite reactivity with amino acids and proteins. Amino Acids (2003) 25:295-311.
40. VIRAG L, SZABO E, GERGELY P, SZABO C: Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol. Lett. (2003) 140-141:113-124.
41. STOCLET JC, MULLER B, GYORGY K, ANDRIANTSIOTHAINA R, KLESCHYOV AL: The inducible nitric oxide synthase in vascular and cardiac tissue. Eur. J. Pharmacol. (1999) 375:139-155.
42. HESS DT, MATSUMOTO A, KIM SO, MARSHALL HE, STAMLER JS: Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. (2005) 6:150-166.
43. CARVER J, DOCTOR A, ZAMAN K, GASTON B: S-nitrosothiol formation. Methods Enzymol. (2005) 396:95-105.
44. RHEE KY, ERDJUMENT-BROMAGE H, TEMPST P, NATHAN CF: S-nitroso proteome of Mycobacterium, tuberculosis: Enzymes of intermediary metabolism and antioxidant defense. Proc Natl. Acad. Sci. USA (2005) 102:467-472.
45. BAROUCH LA, HARRISON RW, SKAF MW et al: Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature (2002) 416:337-339.
46. MATES JM, PEREZ-GOMEZ C, NUNEZ DE CASTRO I: Antioxidant enzymes and human diseases. Clin. Biochem. (1999) 32:595-603.
47. SYDOW K, DAIBER A, OELZE M at el.: Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J. Clin. Invest. (2004) 113:482-489.
48. LIU L, YAN Y, ZENG M et al.: Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell (2004) 116:617-628.
49. FOSTER MW, MCMAHON TJ, STAMLER JS: S-nitrosylation in health and disease. Trends Mol. Med. (2003) 9:160-168.
50. CLANCY RM, LESZCZYNSKA-PIZIAK J, ABRAMSON SB: Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J. Clin. Invest. (1992) 90:1116-1121.
51. HASSOUN PM, YU FS, ZULUETA JJ, WHITE AC, LANZILLO JJ: Effect of nitric oxide and cell redox status on the regulation of endothelial cell xanthine dehydrogenase. Am. J. Physiol. (1995) 268:L809-L817.
52. JOURD'HEUIL D, JOURD'HEUIL FL, KUTCHUKIAN PS, MUSAH RA, WINK DA, GRISHAM MB: Reaction of superoxide and nitric oxide with peroxynitrite. Implications for peroxynitrite-mediated oxidation reactions in vivo. J. Biol. Chem. (2001) 276:28799-28805.
53. SHINYASHIKI M, PAN CJ, LOPEZ BE, FUKUTO JM: Inhibition of the yeast metal reductase heme protein frel by nitric oxide (NO): a model for inhibition of NADPH oxidase by NO. Free Radic. Biol. Med. (2004) 37:713-723.
54. WINK DA, COOK JA, KIM SY et al: Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide-derived reactive intermediates. Chemical aspects involved in the balance between oxidative and nitrosative stress. J. Biol. Chem. (1997) 272:11147-11151.
55. RAJU SV, BAROUCH LA, HARE JM: Nitric oxide and oxidative stress in cardiovascular aging. Sci. Aging Knowledge Environ. (2005) 2005:re4.
56. REITER CD, TENG RJ, BECKMAN JS: Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J. Biol. Chem. (2000) 275:32460-32466.
57. ERWIN PA, LIN AJ, GOLAN DE, MICHEL T: Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. (2005) 280:19888-19894.
58. KWON J, LEE SR, YANG KS et al.: Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. USA (2004) 101:16419-16424.
59. MING XF, VISWAMBHARAN H, BARANDIER C et al: Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. (2002) 22:8467-8477.
60. BIVALACQUA TJ, CHAMPION HC, USTA MF et al.: RhoA/Rho-kinase suppresses endothelialnitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl. Acad Sci. USA (2004) 101:9121-9126.
61. JIN L, YING Z, WEBB RC: Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am. J. Physiol. Heart Circ. Physiol. (2004) 287:H1495-H1500.
62. WANG D, CHABRASHVILI T, WILCOX CS: Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circ. Res. (2004) 94:1436-1442.
63. ZHANG C, HEIN TW, WANG W et al.: Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension (2004) 44:935-943.
64. GOLD ME, WOOD KS, BYRNS RE, FUKUTO J, IGNARRO LJ: NG-methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein. Proc. Natl. Acad. Sci. USA (1990) 87:4430-4434.
65. PEKINER C, KELICEN P, UMA S, MIWA I: Two new nitric oxide synthase inhibitors: pyridoxal aminoguanidine and 8-quinolinecarboxylic hydrazide selectively inhibit basal but not agonist-stimulated release of nitric oxide in rat aorta. Pharmacol. Res. (2002) 46:317-320.
66. BURNETT AL: Novel nitric oxide signaling mechanisms regulate the erectile response. Int. J. Impot. Res. (2004) 16(Suppl. 1):S15-S19.
67. HURT KJ, MUSICKI B, PALESE MA et al.: Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc. Natl. Acad. Sci. USA (2002) 99:4061-4066.
68. HEDLUND P, ASZODI A, PFEIFER A et al.: Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc. Natl. Acad. Sci. USA (2000) 97:2349-2354.
69. CORBIN JD: Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int. J. Impot. Res. (2004) 16(Suppl. 1):S4-S7.
70. ANDERSSON KE: Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J. Urol. (2003) 170:S6-SI3.
71. BIVALACQUA TJ, USTA MF, CHAMPION HC, KADOWITZ PJ, HELLSTROM WJ: Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J. Androl. (2003) 24:S17-S37.
72. JONES RW, REES RW, MINHAS S, RALPH D, PERSAD RA, JEREMY JY: Oxygen free radicals and the penis. Expert Opin. Pharmacother. (2002) 3:889-897.
73. DALEY JT, WATKINS MT, BROWN ML, MARTINEZ V, CUEVAS P, SAENZ DE TEJADA I: Prostanoid production in rabbit corpus cavernosum. II. Inhibition by oxidative stress. J. Urol. (1996) 156:1169-1173.
74. BIVALACQUA TJ, ARMSTRONG JS, BIGGERSTAFF J et al.: Gene transfer of extracellular SOD to the penis reduces 02-* and improves erectile function in aged rats. Am. J. Physiol. Heart Circ. Physiol. (2003) 284:H1408-H1421.
75. KHAN MA, THOMPSON CS, JEREMY JY, MUMTAZ FH, MIKHAILIDIS P, MORGAN RJ: The effect of superoxide dismutase on nitric oxide-mediated and electrical field-stimulated diabetic rabbit cavernosal smooth muscle relaxation. BJU Int. (2001) 87:98-103.
76. AZADZOI KM, SCHULMAN RN, AVIRAM M, SIROKY MB: Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. J. Urol. (2005) 174.386-393.
77. KEEGAN A, COTTER MA, CAMERON NE: Corpus cavernosum dysfunction in diabetic rats: effects of combined alpha-lipoic acid and gamma-linolenic acid treatment. Diabetes Metab. Res. Rev. (2001) 17:380-386.
78. DE YOUNG L, YU D, BATEMAN RM, BROCK GB: Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction, J. Androl. (2004) 25:830-836.
79. RYU JK, LEE T, KIM DJ et al: Free radical-scavenging activity of Korean red ginseng for erectile dysfunction in non-insulin-dependent diabetes mellitus rats. Urology (2005) 65:611-615.
80. HURDAG C, OZKARA H, CITCI S, UYANER I, DEMIRCI C: The effects of alpha-lipoic acid on nitric oxide synthetase dispersion in penile function in streptozotocin-induced diabetic rats. Int. J. Tissue React. (2005) 27:145-150.
81. DALEY JT, BROWN ML, WATKINS T et al.: Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. J. Urol. (1996) 155:1482-1487.
82. SIROKY MB, AZADZOI KM: Vasculogenic erectile dysfunction: newer therapeutic strategies. J. Urol. (2003) 170:S24-S29.
83. KIM N, VARDI Y, PADMA-NATHAN H et al.: Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J. CLin. Invest. (1993) 91:437-442.
84. BIVALACQUA TJ, LIU T, CHAMPION HC, BURNETT AL: Endothelial nitric oxide synthase is a homeostatic regulator of RboA/Rho-kinase activity in the penis. J. Urol. (2005) 173:1041 Abstract.
85. EVLIYAOGLU Y, KAYRIN L, KAYA B: Effect of pentoxifylline on veno-occlusive priapism-induced corporeal tissue lipid peroxidation in a rat model. Urol. Res. (1997) 25:143-147.
86. MUNARRIZ R, PARK K, HUANG YH et al.: Reperfusion of ischemic corporal tissue: physiologic and biochemical changes in an animal model of ischemic priapism. Urology (2003) 62:760-764.
87. POLI G, PAROLA M: Oxidative damage and fibrogenesis. Free Radic. Biol. Med. (1997) 22:287-305.
88. FERRINI M, MAGEE TR, VERNET D, RAJFER J, GONZALEZ-CADAVID NF: Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis. Biol. Reprod. (2001) 64:974-982.
89. BIVALACQUA TJ, DINER EK, NOVAK TE et al.: A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J. Urol. (2000) 163:1992-1998.
90. PODLASEK CA, ZELNER DJ, BERVIG TR, GONZALEZ CM, MCKENNA KE, MCVARY KT: Characterization and localization of nitric oxide synthase isoforms in the BB/WOR diabetic rat. J. Urol. (2001) 166:746-755.
91. USTA MF, TUNCER M, BAYKAL A et al.: Impact of chronic renal failure and peritoneal dialysis fluids on advanced glycation end product and iNOS levels in penile tissue: an experimental study. Urology (2002) 59:953-957.
92. BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active Type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47-52.
93. BURNETT AL: Phosphodiesterase 5 mechanisms and therapeutic applications. Am. J. Cardiol. (2005) 96:29-31.
94. BLOUNT MA, BEASLEY A, ZORAGHI R et al: Binding of tritiated sildenafil, tadafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol. (2004) 66:144-152.
95. SASTRY BK, NARASIMHAN C, REDDY NK, RAJU BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. (2004) 43:1149-1153.
96. MONTORSI F, MAGA T, STRAMBI LF et al.: Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology (2000) 56:906-911.
97. BEHR-ROUSSEL D, GORNY D, MEVEL K et al.: Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur. Urol. (2005) 47:87-91.
98. MUSICKI B, CHAMPION HC, BECKER RE, LIU T. KRAMER MF, BURNETT AL: Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol. Pharmacol. (2005) 68:226-232.
99. DAS S, MAULIK N, DAS DK, KADOWITZ PJ, BIVALACQUA TJ: Cardioprotection with sildenafil, a selective inhibitor of cyclic 3', 5'-monophosphate-specific phosphodiesterase 5. Drugs Exp. Clin. Res. (2002) 28:213-219.
100. KUKREJA RC, OCKAILI R, SALLOUM F et al.: Cardioprotection with phosphodiesterase-5 inhibition-a novel preconditioning strategy. J. Mol. Cell. Cardiol. (2004) 36:165-173.
101. KUKREJA RC, SALLOUM F, DAS A et al.: Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul. Pharmacol. (2005) 42:219-232.
102. BURNETT AL, BIVALACQUA TJ, CHAMPION HC, MUSICKI B: Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology (2006) In Press.
103. BIVALACQUA TJ, CHAMPION HC, MASON W, BURNETT AL: Chronic phosphodiesterase Type 5 inhibitor therapy reduces priapic activity in transgenic sickle cell mice. J. Urol. AUA Abstract (2006) In Press.
104. VALENTE EG, VERNET D, FERRINI MG, QIAN A, RAJFER J, GONZALEZ-CADAVID NF: L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide (2003) 9:229-244.
105. KOUPPARIS AJ, JEREMY JY, MUZAFFAR S, PERSAD R, SHUKLA N: Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int. (2005) 96:423-427.
106. SCATENA R, BOTTONI P, MARTORANA GE, GIARDINA B: Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin. Investig. Drugs (2005) 14:835-846.
107. TRUSS MC, BECKER AJ, DJAMILIAN MH, STIEF CG, JONAS U: Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology (1994) 44:553-556.
108. TARHAN F, KUYUMCUOGLU U, KOLSUZ A, OZGUL A, CANGUVEN O: Effect of intracavernosal sodium nitroprusside in impotence. Urol. Int. (1996) 56:211-214.
109. FU Q, YAO DH, JIANG YQ: A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/ phentolamine in erectile dysfunction patients. Asian J. Androl. (2000) 2:301-303.
110. VERNET D, FERRINI MG, VALENTE EG et al.: Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide (2002) 7:262-276.
111. SEIDLER M, UCKERT S, WALDKIRCH E et al.: In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue. Eur. Urol. (2002) 42:523-528.
112. KALSI JS, KELL PD, CELLEK S, RALPH DJ: NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavemosum, in the absence of endogenous nitric oxide. Int. J. Impot. Res. (2004) 16:195-200.
113. KALSI JS, RALPH DJ, MADGE DJ, KELL PD, CELLEK S: A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. Int. J. Impot. Res. (2004) 16:479-485.
114. SHUKLA N, JONES R, PERSAD R, ANGELINI GD, JEREMY JY: Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaernic rabbits. Eur. J. Pharmacol. (2005) 517:224-231.
115. STASCH JR, BECKER EM, ALONSO-ALIJA C et al.: NO-independent regulatory site on soluble guanylate cyclase. Nature (2001) 410:212-215.
116. BRIONI JD, NAKANE M, HSIEH GC, MORELAND RB, KOLASA T, SULLIVAN JP: Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int. J. Impot. Res. (2002) 14:8-14.
117. MULSCH A, BAUERSACHS J, SCHAFER A, STASCH JP, KAST R, BUSSE R: Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. (1997) 120:681-689.
118. WOHLFART P. MALINSKI T, RUETTEN H et al.: Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. (1999) 128:1316-1322.
119. KALSI JS, REES RW, HOBBS AJ et al.: BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum. in vitro. J. Urol. (2003) 169:761-766.
120. MILLER LN, NAKANE M, HSIEH GC et al.: A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. (2003) 72:1015-1025.
121. GOCMEN C, BUYUKNACAR HS, KOTS AY, MURAD F, KIROGLU O, KUMCU EK: The relaxant activity of 4,7-dimerhyl-1,2,5-oxadiazolo [3,4-d]-pyridazine 11,5,6-trioxide in the mouse corpus cavernosum. J. Pharmacol Exp. Ther. (2006) 316:753-761.
122. DRÖGE W: Aging-related changes in the thiol/disulfide redox state: implications for the use of thiol antioxidants. Exp. Gerontol. (2002) 37:1331-1343.
123. MOK JS, PAISLEY K, MARTIN W. Inhibition of nitrergic neurotransmission in the bovine retractor penis muscle by an oxidant stress: effects of superoxide dismutase mimetics. Br. J. Pharmacol. (1998) 124:111-118.
124. BIVALACQUA TJ, USTA MF KENDIRCI M et al.: Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J. Sex. Med. (2005) 2:187-198.
125. CENA C, BOSCHI D, TRON GC et al.: Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. Bioorg. Med Chem. Lett. (2004) 14:5971-5974.
126. LOPEZ GV, BATTHYANY C, BLANCO F et al.: Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs. Bioorg. Med. Chem. (2005) 13:5787-5796.
127. PORTALUPPI F, BOARI B, MANFREDINI R: Oxidative stress in essential hypertension. Curr. Pharm. Des. (2004) 10:1695-1698.
128. LANDMESSER U, HARRISON DG, DREXLER H: Oxidant stress-a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur. J. Clin. Pharmacol. (2005) 12:1-7.